According to The Insight Partners market research study of ‘Viral Vector & Plasmid DNA Manufacturing Market to 2027 – Global Analysis and Forecast by Product, and Application,’ the global Viral Vector & Plasmid DNA Manufacturing market is expected to reach US$ 2,247.7million by 2027 from US$ 459.4million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. The report highlights trends prevailing in the global viral vector & plasmid DNA manufacturing market and the factors driving market along with those that act as hindrances.

Download Sample PDF Viral Vector & Plasmid DNA Manufacturing Report Copy at: https://www.theinsightpartners.com/sample/TIPRE00003074/ 

Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are naked DNA, particle-based, and chemical-based. Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders, and infectious diseases across the world are expected to upsurge the market growth. Additionally,growth in the global healthcare market is likely to have a positive impact on the market in the coming years.

Market Insights

Increasing Prevalence of Genetic Disorders and Infectious Diseases

According to a study published by National Hemophilia Foundation in 2015, an estimated 400,000 people across the globe are suffering from hemophilia. Further, according to a study published by the NIH in 2019, sickle cell anemia affects an estimated 100,000 people in the US. The application of gene therapy for the treatment of viral infections such as herpes simplex viruses, adeno-associated viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies as one of the prominent treatment alternatives, which will eventually boost the growth of the viral vectors and plasmid DNA manufacturing market during the forecast period.

Gene therapies with the help of viral vectors are widely recommended for a range of monogenic disorders, such as sickle cell anemia, severe combined immunodeficiency, cystic fibrosis, hemophilia, Duchenne muscular dystrophy, Parkinson’s disease, and Gaucher disease. For instance, in October 2019, a group of researchers at the National Institutes of Health (NIH) developed a new improved viral vector for the treatment of sickle cell anemia. According to the researchers, the new vector is 10 times efficient than already existing viral vectors in the market.

Product Insights

Based on product, the viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the larger share of the market in 2019, owing to the factor that these are used in basic research, gene therapy, and vaccine preparation. Moreover, they can be of different types such as retroviruses, lentiviruses, adenoviruses, adeno-associated viruses, and hybrids. Additionally, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. Hence the growing demand is likely to propel the growth of the market at a highest CAGR during the forecast period.

End User Insights

Based on end user, the viral vector & plasmid DNA manufacturing market is segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period. The growing prevalence of cancer is likely to grow market at a faster CAGR.

Strategic Insights

Product launch and expansion are commonly adopted by companies to expand their footprint and product portfolio worldwide in order to meet the growing demand. The market players operating in the viral vector & plasmid DNA manufacturing market adopt the strategy of collaboration and partnership to enlarge customer base across the world, which also permits the players to maintain their brand name in the global market.

Based on Product, the global viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the largest share of the market in 2019owing to the rising preference for viral vectors in gene transfer is evident by the increase in number of clinical trials on viral vector-mediated gene therapy and rising in number of initiative taken by market players. Moreover, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. For instance, in 2019, around 372 clinical trials were registered that involved vector-mediated gene therapy production.

The viral vector & plasmid DNA manufacturing market is expected to grow owing to factors such as growing awareness of gene therapy and increasing prevalence of genetic disorders and infectious diseases across the world. Additionally, growth of the global healthcare market is likely to have a positive impact on the market in the coming years.

Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosynth Biotechnologies, Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec S.A., MassBiologics, Spark Therapeutics, and Uniqure are among the leading companies operating in the viral vector & plasmid DNA manufacturing market.

Global Viral Vector & Plasmid DNA ManufacturingMarket, By Regions, 2019 (%)

Global Viral Vector & Plasmid DNA ManufacturingMarket, By Regions, 2019 (%)

 

The report segments global viral vector & plasmid DNA manufacturing market as follows:

By Product

  • Viral Vectors
  • Non-Viral Vectors

By Application

  • Cancer
  • Inherited Disorders
  • Viral Infections
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • UK
    • Spain
    • Italy
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Middle East & Africa (MEA)
    • Saudi Arabia
    • UAE
    • South Africa
  • South & Central America (SCAM)
    • Brazil
    • Argentina
Buy Complete Viral Vector & Plasmid DNA Manufacturing Report at: https://www.theinsightpartners.com/buy/TIPRE00003074/

Tags: , , , , , , , , , , , , , , ,

See Campaign: https://www.theinsightpartners.com/reports/viral-vector-and-plasmid-dna-manufacturing-market/
Contact Information:
Sameer Joshi +1-646-491-9876 sales@theinsightpartners.com

Tags:
Menafn, iCN Internal Distribution, Research Newswire, English

image

Contact Information:

Sameer Joshi
+1-646-491-9876
sales@theinsightpartners.com